Best Practice & Research Clinical Endocrinology & Metabolism
Volume 24, Issue 2 , Pages 243-262 , April 2010

46,XY DSD due to impaired androgen production

  • Berenice B. Mendonca, M.D

      Affiliations

    • Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
    • Corresponding Author InformationCorresponding author. Tel.: +55 11 30697512; Fax: +55 11 3083 7519.
    • ,
  • Elaine M.F. Costa, M.D

      Affiliations

    • Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
    • ,
  • Alicia Belgorosky, M.D., PhD

      Affiliations

    • Servicio de Endocrinologia, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
    • ,
  • Marco Aurelio Rivarola, M.D

      Affiliations

    • Servicio de Endocrinologia, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
    • ,
  • Sorahia Domenice, M.D

      Affiliations

    • Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

References 

  1. MacLaughlin DT, Donahoe PK. Sex determination and differentiation. The New England Journal of Medicine. 2004;350:367–378
  2. Yao HH, Whoriskey W, Capel B. Desert Hedgehog/Patched 1 signaling specifies fetal Leydig cell fate in testis organogenesis. Genes & Development. 2002;16:1433–1440
  3. Park SY, Tong M, Jameson JL. Distinct roles for steroidogenic factor 1 and desert hedgehog pathways in fetal and adult Leydig cell development. Endocrinology. 2007;148:3704–3710
  4. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocrine Reviews. 2002;23:141–174
  5. Simoni M, Gromoll J, Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocrine Reviews. 1997;18:739–773
  6. Berthezene F, Forest MG, Grimaud JA, et al. Leydig-cell agenesis: a cause of male pseudohermaphroditism. The New England Journal of Medicine. 1976;295:969–972
  7. Brown DM, Markland C, Dehner LP. Leydig cell hypoplasia: a cause of male pseudohermaphroditism. The Journal of Clinical Endocrinology and Metabolism. 1978;46:1–7
  8. Eil C, Austin RM, Sesterhenn I, et al. Leydig cell hypoplasia causing male pseudohermaphroditism: diagnosis 13 years after prepubertal castration. The Journal of Clinical Endocrinology and Metabolism. 1984;58:441–448
  9. Schwartz M, Imperato-McGinley J, Peterson RE, et al. Male pseudohermaphroditism secondary to an abnormality in Leydig cell differentiation. The Journal of Clinical Endocrinology and Metabolism. 1981;53:123–127
  10. Lee PA, Rock JA, Brown TR, et al. Leydig cell hypofunction resulting in male pseudohermaphroditism. Fertility and Sterility. 1982;37:675–679
  11. Latronico AC, Arnhold IJ. Inactivating mutations of LH and FSH receptors–from genotype to phenotype. Pediatric Endocrinology Reviews. 2006;4:28–31
  12. Latronico AC, Anasti J, Arnhold IJ, et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. The New England Journal of Medicine. 1996;334:507–512
  13. Misrahi M, Meduri G, Pissard S, et al. Comparison of immunocytochemical and molecular features with the phenotype in a case of incomplete male pseudohermaphroditism associated with a mutation of the luteinizing hormone receptor. The Journal of Clinical Endocrinology and Metabolism. 1997;82:2159–2165
  14. Laue LL, Wu SM, Kudo M, et al. Compound heterozygous mutations of the luteinizing hormone receptor gene in Leydig cell hypoplasia. Molecular Endocrinology. 1996;10:987–997
  15. Martens JW, Verhoef-Post M, Abelin N, et al. A homozygous mutation in the luteinizing hormone receptor causes partial Leydig cell hypoplasia: correlation between receptor activity and phenotype. Molecular Endocrinology. 1998;12:775–784
  16. Arnhold IJ, de Mendonca BB, Toledo SP, et al. Leydig cell hypoplasia causing male pseudohermaphroditism: case report and review of the literature. Revista do Hospital das Clínicas. 1987;42:227–232
  17. Toledo SP, Arnhold IJ, Luthold W, et al. Leydig cell hypoplasia determining familial hypergonadotropic hypogonadism. Progress in Clinical and Biological Research. 1985;200:311–314
  18. Stavrou SS, Zhu YS, Cai LQ, et al. A novel mutation of the human luteinizing hormone receptor in 46XY and 46XX sisters. The Journal of Clinical Endocrinology and Metabolism. 1998;83:2091–2098
  19. Bruysters M, Christin-Maitre S, Verhoef-Post M, et al. A new LH receptor splice mutation responsible for male hypogonadism with subnormal sperm production in the propositus, and infertility with regular cycles in an affected sister. Human Reproduction. 2008;23:1917–1923
  20. Rogers RM, Garcia A, van den Berg L, et al. Leydig cell hypogenesis: a rare cause of male pseudohermaphroditism and a pathological model for the understanding of normal sexual differentiation. The Journal of Urology. 1982;128:1325–1329
  21. Zenteno JCCP, Kofman-Alfaro S, Mendez JP. Evidence for genetic heterogeneity in male pseudohermaphroditism due to Leydig cell hypoplasia. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3803–3806
  22. Latronico AC. Naturally occurring mutations of the luteinizing hormone receptor gene affecting reproduction. Seminars in Reproductive Medicine. 2000;18:17–20
  23. Latronico AC, Chai Y, Arnhold IJ, et al. A homozygous microdeletion in helix 7 of the luteinizing hormone receptor associated with familial testicular and ovarian resistance is due to both decreased cell surface expression and impaired effector activation by the cell surface receptor. Molecular Endocrinology. 1998;12:442–450
  24. Laue L, Wu SM, Kudo M, et al. A nonsense mutation of the human luteinizing hormone receptor gene in Leydig cell hypoplasia. Human Molecular Genetics. 1995;4:1429–1433
  25. Martens J, Lumbroso S, Verhoef-Post M, et al. Mutant luteinizing hormone receptors in a compound heterozygous patient with complete Leydig cell hypoplasia: abnormal processing causes signaling deficiency. The Journal of Clinical Endocrinology and Metabolism. 2002;87:2506–2513
  26. Huhtaniemi I, Alevizaki M. Gonadotrophin resistance. Best Practice & Research. Clinical Endocrinology & Metabolism. 2006;20:561–576
  27. Richter-Unruh A, Verhoef-Post M, Malak S, et al. Leydig cell hypoplasia: absent luteinizing hormone receptor cell surface expression caused by a novel homozygous mutation in the extracellular domain. The Journal of Clinical Endocrinology and Metabolism. 2004;89:5161–5167
  28. Kossack N, Simoni M, Richter-Unruh A, et al. Mutations in a novel, cryptic exon of the luteinizing hormone/chorionic gonadotropin receptor gene cause male pseudohermaphroditism. PLoS Medicine. 2008;5:e88
  29. Saldanha PH, Arnhold IJ, Mendonca BB, et al. A clinico-genetic investigation of Leydig cell hypoplasia. American Journal of Medical Genetics. 1987;26:337–344
  30. Arnhold IJ, Latronico AC, Batista MC, et al. Clinical features of women with resistance to luteinizing hormone. Clinical Endocrinology. 1999;51:701–707
  31. Arnhold IJ, Latronico AC, Batista MC, et al. Ovarian resistance to luteinizing hormone: a novel cause of amenorrhea and infertility. Fertility and Sterility. 1997;67:394–397
  32. Arnhold IJ, Lofrano-Porto A, Latronico AC. Inactivating mutations of luteinizing hormone beta-subunit or luteinizing hormone receptor cause oligo-amenorrhea and infertility in women. Hormone Research. 2009;71:75–82
  33. Tint GS, Irons M, Elias ER, et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. The New England Journal of Medicine. 1994;330:107–113
  34. Opitz JM. RSH/SLO (“Smith-Lemli-Opitz”) syndrome: historical, genetic, and developmental considerations. American Journal of Medical Genetics. 1994;50:344–346
  35. Fukazawa R, Nakahori Y, Kogo T, et al. Normal Y sequences in Smith-Lemli-Opitz syndrome with total failure of masculinization. Acta Paediatrica. 1992;81:570–572
  36. Joseph DB, Uehling DT, Gilbert E, et al. Genitourinary abnormalities associated with the Smith-Lemli-Opitz syndrome. The Journal of Urology. 1987;137:719–721
  37. Berensztein E, Torrado M, Belgorosky A, et al. Smith-Lemli-Opitz syndrome: in vivo and in vitro study of testicular function in a prepubertal patient with ambiguous genitalia. Acta Paediatrica. 1999;88:1229–1232
  38. Andersson CH. Adrenal insufficiency in Smith-Lemli-Opitz syndrome. American Journal of Medical Genetics. 1999;82:382–384
  39. Fitzky BU, Witsch-Baumgartner M, Erdel M, et al. Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:8181–8186
  40. Irons M, Elias ER, Tint GS, et al. Abnormal cholesterol metabolism in the Smith-Lemli-Opitz syndrome: report of clinical and biochemical findings in four patients and treatment in one patient. American Journal of Medical Genetics. 1994;50:347–352
  41. Kelley RI. RSH/Smith-Lemli-Opitz syndrome: mutations and metabolic morphogenesis. American Journal of Human Genetics. 1998;63:322–326
  42. Ginat S, Battaile KP, Battaile BC, et al. Lowered DHCR7 activity measured by ergosterol conversion in multiple cell types in Smith-Lemli-Opitz syndrome. Molecular Genetics and Metabolism. 2004;83:175–183
  43. Starck L, Lovgren-Sandblom A, Bjorkhem I. Simvastatin treatment in the SLO syndrome: a safe approach?. American Journal of Medical Genetics. 2002;113:183–189
  44. Yu H, Patel SB. Recent insights into the Smith-Lemli-Opitz syndrome. Clinical Genetics. 2005;68:383–391
  45. Miller WL. StAR search–what we know about how the steroidogenic acute regulatory protein mediates mitochondrial cholesterol import. Journal of Molecular Endocrinology. 2007 Mar;21(3):589–601
  46. Jefcoate C. High-flux mitochondrial cholesterol trafficking, a specialized function of the adrenal cortex. The Journal of Clinical Investigation. 2002;110:881–890
  47. Prader A, Gurtner HP. [The syndrome of male pseudohermaphrodism in congenital adrenocortical hyperplasia without overproduction of androgens (adrenal male pseudohermaphrodism)], Helvetica Paediatrica Acta. 1955;10:397–412
  48. Sugawara T, Holt JA, Driscoll D, et al. Human steroidogenic acute regulatory protein: functional activity in COS-1 cells, tissue-specific expression, and mapping of the structural gene to 8p11.2 and a pseudogene to chromosome 13. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:4778–4782
  49. Miller WL. Molecular biology of steroid hormone synthesis. Endocrine Reviews. 1988;9:295–318
  50. Bose HS, Sugawara T, Strauss JF, et al. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. The New England Journal of Medicine. 1996;335:1870–1878
  51. Baker BY, Lin L, Kim CJ, et al. Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4781–4785
  52. Lin D, Gitelman SE, Saenger P, et al. Normal genes for the cholesterol side chain cleavage enzyme, P450scc, in congenital lipoid adrenal hyperplasia. The Journal of Clinical Investigation. 1991;88:1955–1962
  53. Hauffa BP, Miller WL, Grumbach MM, et al. Congenital adrenal hyperplasia due to deficient cholesterol side-chain cleavage activity (20, 22-desmolase) in a patient treated for 18 years. Clinical Endocrinology. 1985;23:481–493
  54. Morohashi K, Sogawa K, Omura T, et al. Gene structure of human cytochrome P-450(SCC), cholesterol desmolase. Journal of Biochemistry. 1987;101:879–887
  55. Hiort O, Holterhus PM, Werner R, et al. Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46, XY sex reversal, and severe adrenal failure. The Journal of Clinical Endocrinology and Metabolism. 2005;90:538–541
  56. Kim CJ, Lin L, Huang N, et al. Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, p450scc. The Journal of Clinical Endocrinology and Metabolism. 2008;93:696–702
  57. Rubtsov P, Karmanov M, Sverdlova P, et al. A novel homozygous mutation in CYP11A1 gene is associated with late-onset adrenal insufficiency and hypospadias in a 46, XY patient. The Journal of Clinical Endocrinology and Metabolism. 2009;94:936–939
  58. Tajima T, Fujieda K, Kouda N, et al. Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46, XY sex reversal and adrenal insufficiency. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3820–3825
  59. al Kandari H, Katsumata N, Alexander S, et al. Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46, XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2821–2826
  60. Katsumata N, Ohtake M, Hojo T, et al. Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans. The Journal of Clinical Endocrinology and Metabolism. 2002;87:3808–3813
  61. Bongiovanni AM. The adrenogenital syndrome with deficiency of 3 beta-hydroxysteroid dehydrogenase. The Journal of Clinical Investigation. 1962;41:2086–2092
  62. Mason JI, Ushijima K, Doody KM, et al. Regulation of expression of the 3 beta-hydroxysteroid dehydrogenases of human placenta and fetal adrenal. The Journal of Steroid Biochemistry and Molecular Biology. 1993;47:151–159
  63. Rheaume E, Simard J, Morel Y, et al. Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene. Nature Genetics. 1992;1:239–245
  64. Mendonca BB, Bloise W, Arnhold IJ, et al. Male pseudohermaphroditism due to nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency: gender role change and absence of gynecomastia at puberty. The Journal of Steroid Biochemistry. 1987;28:669–675
  65. Paula FJ, Dick-de-Paula I, Pontes A, et al. Hyperandrogenism due to 3 beta-hydroxysteroid dehydrogenase deficiency with accessory adrenocortical tissue: a hormonal and metabolic evaluation. Brazilian Journal of Medical and Biological Research. 1994;27:1149–1158
  66. Marui S, Castro M, Latronico AC, et al. Mutations in the type II 3beta-hydroxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls. Clinical Endocrinology. 2000;52:67–75
  67. Mermejo LM, Elias LL, Marui S, et al. Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. The Journal of Clinical Endocrinology and Metabolism. 2005;90:1287–1293
  68. Mendonca BB, Russell AJ, Vasconcelos-Leite M, et al. Mutation in 3 beta-hydroxysteroid dehydrogenase type II associated with pseudohermaphroditism in males and premature pubarche or cryptic expression in females. Journal of Molecular Endocrinology. 1994;12:119–122
  69. Moisan AM, Ricketts ML, Tardy V, et al. New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. The Journal of Clinical Endocrinology and Metabolism. 1999;84:4410–4425
  70. Simard J, Rheaume E, Mebarki F, et al. Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency. The Journal of Steroid Biochemistry and Molecular Biology. 1995;53:127–138
  71. Sutcliffe RG, Russell AJ, Edwards CR, et al. Human 3 beta-hydroxysteroid dehydrogenase: genes and phenotypes. Journal of Molecular Endocrinology. 1996;17:1–5
  72. Russell AJ, Wallace AM, Forest MG, et al. Mutation in the human gene for 3 beta-hydroxysteroid dehydrogenase type II leading to male pseudohermaphroditism without salt loss. Journal of Molecular Endocrinology. 1994;12:225–237
  73. Matteson KJ, Picado-Leonard J, Chung BC, et al. Assignment of the gene for adrenal P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase) to human chromosome 10. The Journal of Clinical Endocrinology and Metabolism. 1986;63:789–791
  74. Martin RM, Lin CJ, Costa EM, et al. P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. The Journal of Clinical Endocrinology and Metabolism. 2003;88:5739–5746
  75. Biglieri EG, Herron MA, Brust N. 17-hydroxylation deficiency in man. The Journal of Clinical Investigation. 1966;45:1946–1954
  76. New MI. Male pseudohermaphroditism due to 17 alpha-hydroxylase deficiency. The Journal of Clinical Investigation. 1970;49:1930–1941
  77. Yanase T, Simpson ER, Waterman MR. 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocrine Reviews. 1991;12:91–108
  78. Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinology and Metabolism Clinics of North America. 2001;30:101–119vii
  79. Zachmann M. Recent aspects of steroid biosynthesis in male sex differentiation. Clinical studies. Hormone Research. 1992;38:211–216
  80. Rosa S. P450c17 deficiency: clinical and molecular characterization of six patients. The Journal of Clinical Endocrinology and Metabolism. 2007;92:1000–1007
  81. Zachmann M, Vollmin JA, Hamilton W, et al. Steroid 17,20-desmolase deficiency: a new cause of male pseudohermaphroditism. Clinical Endocrinology. 1972;1:369–385
  82. Geller DH, Auchus RJ, Miller WL. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Molecular Endocrinology. 1999;13:167–175
  83. Hershkovitz E, Parvari R, Wudy SA, et al. Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2008;93:3584–3588
  84. Saez JM, De Peretti E, Morera AM, et al. Familial male pseudohermaphroditism with gynecomastia due to a testicular 17-ketosteroid reductase defect. I. Studies in vivo. The Journal of Clinical Endocrinology and Metabolism. 1971;32:604–610
  85. Boehmer AL, Brinkmann AO, Sandkuijl LA, et al. 17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. The Journal of Clinical Endocrinology and Metabolism. 1999;84:4713–4721
  86. Andersson S, Moghrabi N. Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases. Steroids. 1997;62:143–147
  87. Andersson S, Geissler WM, Wu L, et al. Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency. The Journal of Clinical Endocrinology and Metabolism. 1996;81:130–136
  88. Lee YS, Kirk JM, Stanhope RG, et al. Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls. Clinical Endocrinology. 2007;67:20–28
  89. Mendonca BB, Inacio M, Arnhold IJ, et al. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore). 2000;79:299–309
  90. Bertelloni S, Maggio MC, Federico G, et al. 17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal. Gynecological Endocrinology. 2006;22:488–494
  91. Wilson JD. Androgens, androgen receptors, and male gender role behavior. Hormones Behavior. 2001;40:358–366
  92. Imperato-McGinley J, Peterson RE, Gautier T, et al. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency. The New England Journal of Medicine. 1979;300:1233–1237
  93. Imperato-McGinley J, Peterson RE, Stoller R, et al. Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: gender role change with puberty. The Journal of Clinical Endocrinology and Metabolism. 1979;49:391–395
  94. Rosler A, Kohn G. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: studies on the natural history of the defect and effect of androgens on gender role. Journal of Steroid Biochemistry. 1983;19:663–674
  95. Mendonca BB, Arnhold IJ, Bloise W, et al. 17Beta-hydroxysteroid dehydrogenase 3 deficiency in women. The Journal of Clinical Endocrinology and Metabolism. 1999;84:802–804
  96. Rosler A, Silverstein S, Abeliovich D. A (R80Q) mutation in 17 beta-hydroxysteroid dehydrogenase type 3 gene among Arabs of Israel is associated with pseudohermaphroditism in males and normal asymptomatic females. The Journal of Clinical Endocrinology and Metabolism. 1996;81:1827–1831
  97. Fluck CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nature Genetics. 2004;36:228–230
  98. Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 2004;363:2128–2135
  99. Huang N, Pandey AV, Agrawal V, et al. Diversity and function of mutations in p450 oxidoreductase in patients with antley-bixler syndrome and disordered steroidogenesis. American Journal of Human Genetics. 2005;76:729–749
  100. Porter TD. The roles of cytochrome b5 in cytochrome P450 reactions. Journal of Biochemical and Molecular Toxicology. 2002;16:311–316
  101. Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. The New England Journal of Medicine. 1986;314:757–761
  102. Giordano SJ, Kaftory A, Steggles AW. A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism. Human Genetics. 1994;93:568–570
  103. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annual Review of Biochemistry. 1994;63:25–61
  104. Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. The Journal of Clinical Investigation. 1993;92:903–910
  105. Wigley WC, Prihoda JS, Mowszowicz I, et al. Natural mutagenesis study of the human steroid 5 alpha-reductase 2 isozyme. Biochemistry. 1994;33:1265–1270
  106. Thigpen AE, Davis DL, Milatovich A, et al. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. The Journal of Clinical Investigation. 1992;90:799–809
  107. Andersson S, Berman DM, Jenkins EP, et al. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature. 1991;354:159–161
  108. Mendonca BB, Inacio M, Costa EM, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore). 1996;75:64–76
  109. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213–1215
  110. Imperato-McGinley J, Miller M, Wilson JD, et al. A cluster of male pseudohermaphrodites with 5 alpha-reductase deficiency in Papua New Guinea. Clinical Endocrinology. 1991;34:293–298
  111. Mendonca BB, Inacio M, Costa EMF, et al. Male pseudohermaphroditism due to 5 alfa reductase 2 deficiency: outcome of a Brazilian cohort. The Endocrinologist. 2003;13:201–204
  112. Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocrine Reviews. 1993;14:577–593
  113. Mendonca BB, Domenice S, Arnhold IJ, et al. 46, XY disorders of sex development. Clinical Endocrinology. 2009;70:173–187
  114. Chavez B, Valdez E, Vilchis F. Uniparental disomy in steroid 5alpha-reductase 2 deficiency. The Journal of Clinical Endocrinology and Metabolism. 2000;85:3147–3150
  115. Imperato-McGinley J. 5 alpha-reductase-2 deficiency. Current Therapy in Endocrinology and Metabolism. 1997;6:384–387
  116. Imperato-McGinley J, Peterson RE, Gautier T, et al. Decreased urinary C19 and C21 steroid 5 alpha-metabolites in parents of male pseudohermaphrodites with 5 alpha-reductase deficiency: detection of carriers. The Journal of Clinical Endocrinology and Metabolism. 1985;60:553–558
  117. Arnhold IJ, Mendonca BB, Diaz JA, et al. Prepubertal male pseudohermaphroditism due to 17-ketosteroid reductase deficiency: diagnostic value of a hCG test and lack of HLA association. The Journal of Clinical Investigation. 1988;11:319–322
  118. Garel L. Abnormal sex differentiation: who, how and when to image. Pediatric Radiology. 2008;38(Suppl. 3):S508–S511

PII: S1521-690X(09)00144-4

doi: 10.1016/j.beem.2009.11.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 24, Issue 2 , Pages 243-262 , April 2010

Article Tools

* Image Usage & Resolution